Skip to main content
Publications
Goyal RK , Cuyun Carter G, Nagar SP , Nash Smyth E, Price GL, Parikh RC , Huang YJ, Li L, Davis KL , Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States . Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L , Clark M , Williams N, Chen Z, Ardeleanu M, Akinlade B, Graham NMH, Pirozzi G, Staudinger H, Plaum S, Radin A, Gadkari A. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis . Br J Dermatol. 2019 Oct;181(4):761-9. doi: 10.1111/bjd.17744
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D , Bennett L , Proctor C, Gutierrez L , Andrews E, Johannes C . Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe . Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C , Odom D , Gutierrez L , Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union . Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.